Nilotinib and dasatinib first-line: are we ready for imatinib replacement?

Hagop M. Kantarjian, Francis J. Giles, Kapil N. Bhalla, Javier Pinilla-Ibarz, Richard A. Larson, Norbert Gattermann, Oliver G. Ottmann, Andreas Hochhaus, Jerald P. Radich, Giuseppe Saglio, Timothy P. Hughes, Giovanni Martinelli, Dong-Wook Kim, Yaping Shou, Neil J. Gallagher, Rick Blakesley, Michele Baccarani, Jorge Cortes, Philipp D. le Coutre, Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results Blood. ,vol. 117, pp. 1141- 1145 ,(2011) , 10.1182/BLOOD-2010-03-277152

David Marin, Dragana Milojkovic, Eduardo Olavarria, Jamshid S. Khorashad, Hugues de Lavallade, Alistair G. Reid, Letizia Foroni, Katayoun Rezvani, Marco Bua, Francesco Dazzi, Jiri Pavlu, Matthias Klammer, Jaspal S. Kaeda, John M. Goldman, Jane F. Apperley, European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. Blood. ,vol. 112, pp. 4437- 4444 ,(2008) , 10.1182/BLOOD-2008-06-162388

Yesid Alvarado, Hagop Kantarjian, Susan O'Brien, Stefan Faderl, Gautam Borthakur, Jan Burger, William Wierda, Guillermo Garcia-Manero, Jianqin Shan, Jorge Cortes, Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase. Cancer. ,vol. 115, pp. 3709- 3718 ,(2009) , 10.1002/CNCR.24418

N. P. Shah, D.-W. Kim, H. Kantarjian, P. Rousselot, P. E. D. Llacer, A. Enrico, J. Vela-Ojeda, R. T. Silver, H. J. Khoury, M. C. Muller, A. Lambert, Y. Matloub, A. Hochhaus, Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib Haematologica. ,vol. 95, pp. 232- 240 ,(2010) , 10.3324/HAEMATOL.2009.011452

Massimo Breccia, Sonia M. Orlandi, Roberto Latagliata, Sara Grammatico, Daniela Diverio, Marco Mancini, Giuseppina Loglisci, Adriano Salaroli, Vincenzo Federico, Michelina Santopietro, Giuliana Alimena, Suboptimal response to imatinib according to 2006–2009 European LeukaemiaNet criteria: a ‘grey zone’ at 3, 6 and 12 months identifies chronic myeloid leukaemia patients who need early intervention British Journal of Haematology. ,vol. 152, pp. 119- 121 ,(2011) , 10.1111/J.1365-2141.2010.08380.X

Jerald P. Radich, Chronic Myeloid Leukemia 2010: Where Are We Now and Where Can We Go? Hematology. ,vol. 2010, pp. 122- 128 ,(2010) , 10.1182/ASHEDUCATION-2010.1.122

Jorge E. Cortes, Dan Jones, Susan O'Brien, Elias Jabbour, Marina Konopleva, Alessandra Ferrajoli, Tapan Kadia, Gautam Borthakur, Denise Stigliano, Jianqin Shan, Hagop Kantarjian, Nilotinib As Front-Line Treatment for Patients With Chronic Myeloid Leukemia in Early Chronic Phase Journal of Clinical Oncology. ,vol. 28, pp. 392- 397 ,(2010) , 10.1200/JCO.2009.25.4896

Jorge E. Cortes, Michele Baccarani, François Guilhot, Brian J. Druker, Susan Branford, Dong-Wook Kim, Fabrizio Pane, Ricardo Pasquini, Stuart L. Goldberg, Matt Kalaycio, Beatriz Moiraghi, Jacob M. Rowe, Elena Tothova, Carmino De Souza, Marc Rudoltz, Richard Yu, Tillmann Krahnke, Hagop M. Kantarjian, Jerald P. Radich, Timothy P. Hughes, Phase III, Randomized, Open-Label Study of Daily Imatinib Mesylate 400 mg Versus 800 mg in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase Using Molecular End Points: Tyrosine Kinase Inhibitor Optimization and Selectivity Study web science. ,vol. 28, pp. 424- 430 ,(2010) , 10.1200/JCO.2009.25.3724

Michael Deininger, Stephen G O'Brien, François Guilhot, John M Goldman, Andreas Hochhaus, Timothy P. Hughes, Jerald P. Radich, Alan K. Hatfield, Manisha Mone, Jeiry Filian, John Reynolds, Insa Gathmann, Richard A. Larson, Brian J. Druker, International randomized study of interferon vs STI571 (IRIS) 8-year follow up : Sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib Blood. ,vol. 114, pp. 1126- 1126 ,(2009) , 10.1182/BLOOD.V114.22.1126.1126

Timothy P. Hughes, Andreas Hochhaus, Giuseppe Saglio, Dong-Wook Kim, Saengsuree Jootar, Philipp D. le Coutre, Josy Reiffers, Ricardo Pasquini, Clarisse Lobo, Richard E. Clark, Neil J. Gallagher, Albert Hoenekopp, Ariful Haque, Richard A. Larson, Hagop M. Kantarjian, ENESTnd Update: Continued Superiority of Nilotinib Versus Imatinib In Patients with Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP) Blood. ,vol. 116, pp. 207- 207 ,(2010) , 10.1182/BLOOD.V116.21.207.207